12 papers in the library · 749 citations · publishing 2016-2026
CNS Drugs March 24, 2026 Mathieu Seynaeve, Fiona Dunbar, Chandni Hindocha et al.
Intranasal 5-MeO-DMT Concomitant with SSRI for Treatment-Resistant Depression: A Proof-of-Concept Trial.
Journal of Psychopharmacology May 20, 2022 Matthew B. Wall, Tom P. Freeman, Chandni Hindocha et al. 21 citations
Background: Cannabidiol (CBD) and Δ 9 -tetrahydrocannabinol (THC) are the two major constituents of cannabis with contrasting mechanisms of action. THC is the major psychoactive, addiction-promoting, and psychotomimetic compound, while CBD may have opposite effects. The brain effects of these drugs alone and in combination are poorly understood. In particular, the striatum is implicated in the...
Journal of Psychopharmacology January 9, 2021 Abigail M. Freeman, Claire Mokrysz, Chandni Hindocha et al. 6 citations
BACKGROUND: While the acute effects of cannabis are relatively benign for most users, some individuals experience significant adverse effects. This study aimed to identify whether variation in schizotypal personality traits and frequency of cannabis use influence the acute effects of delta-9-tetrahydrocannabinol (THC). METHODS: Individual participant data from four double-blind, randomised,...
bioRxiv (Cold Spring Harbor Laboratory) November 21, 2020 Matthew B. Wall, Tom P. Freeman, Chandni Hindocha et al. 4 citations preprint
Abstract Cannabidiol (CBD) and Δ9-tetrahydrocannabinol (THC) are two major constituents of cannabis with contrasting mechanisms of action. THC is the major psychoactive, addiction-promoting, and psychotomimetic compound, while CBD may have somewhat opposite effects. The brain effects of these drugs alone and in combination are poorly understood. In particular the striatum is implicated in the...
Journal of Psychopharmacology August 5, 2020 Will Lawn, J. P. Hill, Chandni Hindocha et al. 23 citations
BACKGROUND: Cannabidiol has potential therapeutic benefits for people with psychiatric disorders characterised by reward function impairment. There is existing evidence that cannabidiol may influence some aspects of reward processing. However, it is unknown whether cannabidiol acutely affects brain function underpinning reward anticipation and feedback. HYPOTHESES: We predicted that cannabidiol...
Translational Psychiatry May 12, 2020 Chandni Hindocha, Diego Quattrone, Tom P. Freeman et al.
Epidemiological and biological evidence support the association between heavy cannabis use and psychosis. However, it is unclear which cannabis users are susceptible to its psychotogenic effect. Therefore, understanding genetic factors contributing to this relationship might prove an important strategy to identify the mechanisms underlying cannabis-associated psychotic experiences. We aimed to...
Psychological Medicine April 28, 2020 Claire Mokrysz, Natacha D. C. Shaban, Tom P. Freeman et al. 24 citations
BACKGROUND: Acute cannabis administration can produce transient psychotic-like effects in healthy individuals. However, the mechanisms through which this occurs and which factors predict vulnerability remain unclear. We investigate whether cannabis inhalation leads to psychotic-like symptoms and speech illusion; and whether cannabidiol (CBD) blunts such effects (study 1) and adolescence...
Journal of Psychopharmacology April 23, 2019 Matthew B. Wall, Rebecca Pope, Tom P. Freeman et al. 89 citations
BACKGROUND: -tetrahydrocannabinol (THC) and cannabidiol (CBD). THC is the main psychoactive component; CBD may buffer the user against the harmful effects of THC. AIMS: We examined the effects of two strains of cannabis and placebo on the human brain's resting-state networks using fMRI. METHODS: Seventeen healthy volunteers (experienced with cannabis, but not regular users) underwent three drug...
Pharmacology & Therapeutics October 20, 2018 Michael Bloomfield, Chandni Hindocha, Sebastian F Green et al. 236 citations
receptor. Acutely, cannabis and THC produce a range of effects on several neurocognitive and pharmacological systems. These include effects on executive, emotional, reward and memory processing via direct interactions with the endocannabinoid system and indirect effects on the glutamatergic, GABAergic and dopaminergic systems. Cannabidiol, a non-intoxicating cannabinoid found in some forms of...
Psychopharmacology October 30, 2017 J. B. Stroud, Tom P. Freeman, Robert Leech et al. 102 citations
RATIONALE: Depressed patients robustly exhibit affective biases in emotional processing which are altered by SSRIs and predict clinical outcome. OBJECTIVES: The objective of this study is to investigate whether psilocybin, recently shown to rapidly improve mood in treatment-resistant depression (TRD), alters patients' emotional processing biases. METHODS: Seventeen patients with...
The International Journal of Neuropsychopharmacology August 30, 2017 Tom P. Freeman, Rebecca Pope, Matthew B. Wall et al. 67 citations
Background: Despite the current shift towards permissive cannabis policies, few studies have investigated the pleasurable effects users seek. Here, we investigate the effects of cannabis on listening to music, a rewarding activity that frequently occurs in the context of recreational cannabis use. We additionally tested how these effects are influenced by cannabidiol, which may offset...
Psychopharmacology September 2, 2016 Will Lawn, Tom P. Freeman, Rebecca Pope et al. 177 citations
RATIONALE: Anecdotally, both acute and chronic cannabis use have been associated with apathy, amotivation, and other reward processing deficits. To date, empirical support for these effects is limited, and no previous studies have assessed both acute effects of Δ-9-tetrahydrocannabinol (THC) and cannabidiol (CBD), as well as associations with cannabis dependence. OBJECTIVES: The objectives of...